STOCK TITAN

Bright Green Corp Stock Price, News & Analysis

BGXX Nasdaq

Welcome to our dedicated page for Bright Green news (Ticker: BGXX), a resource for investors and traders seeking the latest updates and insights on Bright Green stock.

Stay informed about Bright Green Corporation with real-time news coverage tracking developments in DEA-licensed pharmaceutical manufacturing, controlled substance production, and plant-based API development. Our news feed delivers updates on regulatory approvals, facility expansions, production milestones, and strategic partnerships affecting the company's operations in Schedule I and Schedule II pharmaceutical manufacturing.

Bright Green Corporation operates as a DEA-licensed manufacturer specializing in plant-based pharmaceutical APIs including psilocybin, psilocyn, mescaline, peyote, and opium poppy derivatives. The company's Chapter 11 restructuring process and merger with PharmAGRI Capital Partners represent significant corporate developments affecting its business trajectory and market position in domestic pharmaceutical manufacturing.

Monitor news affecting Bright Green's production capabilities, federal contract opportunities, regulatory compliance status, and technological implementations in pharmaceutical automation. Coverage includes developments related to the company's New Mexico facilities, DEA registration status, partnership agreements with pharmaceutical customers, and progress in establishing domestic supply chains for controlled substance APIs.

The news feed tracks announcements regarding the company's restructuring plan, bankruptcy proceedings, creditor negotiations, and emergence timeline. Stay updated on operational developments at the Grants manufacturing facility, research activities in Albuquerque, and strategic initiatives related to the "seed to syringe" pharmaceutical production model.

Access comprehensive coverage of market developments affecting plant-based pharmaceutical manufacturing, regulatory changes impacting controlled substance production, and industry trends in domestic API supply chains. Our real-time news aggregation ensures you receive timely updates on corporate actions, financial developments, regulatory filings, and strategic announcements affecting Bright Green Corporation's business operations and market position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.66%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.2%
Tags
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.92%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.03%
Tags
private placement
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.77%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.12%
Tags
private placement

FAQ

What is the current stock price of Bright Green (BGXX)?

The current stock price of Bright Green (BGXX) is $0.038 as of February 24, 2025.

What is the market cap of Bright Green (BGXX)?

The market cap of Bright Green (BGXX) is approximately 11.4M.
Bright Green Corp

Nasdaq:BGXX

BGXX Rankings

BGXX Stock Data

11.37M
71.60M
62.55%
0.39%
0.39%
Drug Manufacturers - Specialty & Generic
Medicinal Chemicals & Botanical Products
Link
United States
FT. LAUDERDALE